Here are six things to know:
1. The treatment is delivered via a highly-penetrative ointment that creates stem cells deep below the skin.
2. TetraStem is a tetracycline-based topic antibiotic that is FDA-approved to treat cuts and burns. Five years ago, the drug’s ability to induce stem-cell healing became apparent in animal research before successfully working on humans.
3. Old spinal cord injuries are typically very difficult to treat, but Phillips has managed to obtain good results after treating patients.
4. The treatment doesn’t require hospitalization due to its topical nature and has yet to exhibit any side effects.
5. Phillips is a not-for-profit FDA-registered drug manufacturing company.
6. TetraStem is expected to be transferred to a larger pharmaceutical company for high volume production.
More spine-related articles:
Dr. Daniel Fulkerson authors book about life as a pediatric neurosurgeon: 5 insights
Spinal cord patients risk infections during hospital stays — 6 takeaways
Dr. Robert Galler steps into neurosurgery director role at Peconic Bay Medical Center: 5 highlights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.